More Sudhakar W, Parande Malangori Abdulgani, Kamble Sanjeev W, Kamble Manjunath S
State TB Training and Demonstration Centre, Pune, Maharashtra, India.
Department of Community Medicine, Byramjee Jeejebhoy Government Medical College, Pune, Maharashtra, India.
J Family Med Prim Care. 2017 Jan-Mar;6(1):29-33. doi: 10.4103/2249-4863.214954.
Drug-resistant tuberculosis (TB) strains have evolved mainly due to incomplete or improper treatment of TB patients and are one of the hurdles in controlling TB problem. It is better to understand the magnitude and comorbidities associated with drug-resistant TB.
(1) To study some of the sociodemographic profile and history of TB treatment of drug-resistant TB cases. (2) To study their drug-resistance pattern and their comorbidity profile.
It was a record-based study descriptive, cross-sectional study of drug-resistant TB cases that were referred to State TB Training and Demonstration Centre (STDC).
The data were collected by means of use of TB patient treatment register of those tested at STDC during first two quarters of the year 2012 (from January to June 2012). Sputum samples of all the cases were subjected to concentrated microscopy, and all positive samples were tested by GeneXpert and Line Probe Assay for drug susceptibility testing (DST) for isoniazid and rifampicin.
The findings were analyzed with Epi info7, using the mean, standard deviation, Chi-square test.
The mean age of the patients was 35.65 ± 13.59 years, majority 71.87% were males. The majority of patients 72.91% had the previous history of TB. A majority 68.75% of the patients had acquired drug resistance, and 73.95% of cases were suffering from multidrug-resistant TB. A total of 28.13% patients had self-reported comorbidity. A majority 62.5% had failure as the treatment outcome for the current episode of TB and mortality was seen in 12.5% cases.
Majority had failure as a treatment outcome due to advanced disease status or late diagnosis. Rapid diagnosis and DST for first- and second-line drugs will greatly improve the clinical outcome.
耐药结核病菌株的出现主要是由于结核病患者治疗不彻底或不恰当，这是控制结核病问题的障碍之一。更好地了解与耐药结核病相关的规模和合并症很有必要。
（1）研究耐药结核病病例的一些社会人口学特征和结核病治疗史。（2）研究其耐药模式和合并症情况。
这是一项基于记录的描述性横断面研究，研究对象为转诊至州结核病培训与示范中心（STDC）的耐药结核病病例。
通过使用2012年前两个季度（2012年1月至6月）在STDC接受检测的结核病患者治疗登记册收集数据。所有病例的痰标本均进行浓缩显微镜检查，所有阳性标本均通过GeneXpert和线性探针分析进行异烟肼和利福平药敏试验（DST）。
使用Epi info7对研究结果进行分析，采用均值、标准差、卡方检验。
患者的平均年龄为35.65±13.59岁，大多数（71.87%）为男性。大多数患者（72.91%）有结核病既往史。大多数患者（68.75%）获得性耐药，73.95%的病例患有耐多药结核病。共有28.13%的患者自述有合并症。大多数（62.5%）患者本次结核病治疗结局为失败，12.5%的病例出现死亡。
由于病情严重或诊断延迟，大多数患者治疗结局为失败。对一线和二线药物进行快速诊断和药敏试验将大大改善临床结局。
